Immunotherapy washout study for invasive ductal breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how long it takes for a type of immunotherapy drug to clear out of your body in women with invasive ductal breast cancer who are about to start treatment before surgery. It may help doctors decide the best timing for future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive ductal breast cancer (a common type of breast cancer).
- You are planning to receive chemotherapy or other treatment before surgery (neoadjuvant therapy).
- If a lymph node was thought to have cancer, a needle biopsy must show it does not have cancer.
- A biopsy of a lymph node that seemed healthy must not show cancer.
- You do not have any other active cancer, you are not pregnant, and you do not have a weakened immune system.
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing if a less invasive sentinel lymph node biopsy can replace more extensive lymph node removal in women with inflammatory breast cancer who have had chemotherapy and whose nodes appear cancer-free. This could help avoid unnecessary side effects.
This study looks at whether it’s safe and effective to avoid removing many underarm lymph nodes in some people who, after chemotherapy, still seem to have only tiny (“micro”) cancer deposits in the sentinel lymph node. It may help reduce treatment side effects while keeping cancer control.
This study looks at whether some breast cancer patients can safely skip a surgery that removes lymph nodes in the armpit after their initial (pre-surgery) treatment shows the armpit is likely clear. It may reduce surgical side effects if the armpit truly responds well.
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
This trial studies how doctors should operate on lymph nodes after you finish chemotherapy given before surgery. It may help improve treatment planning for people whose breast cancer has spread to nearby lymph nodes, but not to distant organs.
This trial tests whether patients with stage 3 melanoma that shrinks significantly after initial immunotherapy can safely avoid having all their lymph nodes surgically removed. Instead, only the main affected node is removed for testing.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.